Study design, baseline and open-label results from XTEND-CIU: A phase IV, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of omalizumab through 48 weeks in patients with chronic idiopathic urticaria

Category Primary study
JournalJournal of Allergy and Clinical Immunology
Year 2017
This article has no abstract
Epistemonikos ID: abd9ecb25a112931dd21758c7c8c2a5b32e2b5d2
First added on: Feb 08, 2025